Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura. 2008

Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
Division of Hematology/Oncology, Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran. eshahgholi@sina.tums.ac.ir

OBJECTIVE The purpose of this study was to compare the efficacy and side effects of intravenous immunoglobulin (IVIG) with intravenous anti-D immunoglobulin for treatment of newly diagnosed acute childhood Idiopathic thrombocytopenic purpura (ITP). METHODS Children (6 months to 14 years) with newly diagnosed acute ITP and platelet count below 20,000/ microL were randomized to receive single dose intravenous 75 microg/kg anti-D or 1g/kg IVIG for two consecutive days (total dose 2 g/kg). Response rate defined as a platelet count over 20,000 / microL 72 hours after initial treatment. RESULTS Eighty one patients (52 male and 29 female) with mean age of 5 years and 3 months randomly divided in anti-D group (n=42) and IVIG group (n=39). Mean baseline (pretreatment) platelet counts were 15406 / microL and 15230/ microL in anti-D and IVIG group, respectively. The response rate in IVIG group (98%) was more significant than anti-D group (76%); (P = 0.017). After 7 days the platelet counts of all patients in IVIG group were more than 20,000/ microL while in anti-D group 12% had platelet counts below 20,000/ microL. CONCLUSIONS In acute childhood ITP, initial treatment with IVIG (2g/Kg in divided dose) increased platelet count more rapidly and more significant than intravenous anti-D (single dose of 75 microg/kg) within the first 72 hours.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
April 1998, Blood,
Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
January 1999, The Journal of pediatrics,
Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
November 1995, Lancet (London, England),
Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
December 2003, American journal of hematology,
Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
March 2000, American journal of hematology,
Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
April 2010, British journal of haematology,
Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
January 2008, Acta haematologica,
Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
November 2001, Current opinion in hematology,
Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
January 1993, Pediatric hematology and oncology,
Elham Shahgholi, and Parvaneh Vosough, and Kambiz Sotoudeh, and Khadijeh Arjomandi, and Shahla Ansari, and Soraya Salehi, and Mohammad Faranoush, and Mohammad Ali Ehsani
November 2004, American journal of hematology,
Copied contents to your clipboard!